---
layout: minimal-medicine
title: Tolrestat
---

# Tolrestat
### Generic Name
Tolrestat

### Usage
Tolrestat is an aldose reductase inhibitor.  Its primary intended use was to manage complications of diabetes, specifically those related to the accumulation of sorbitol in tissues.  This accumulation, a consequence of increased aldose reductase activity in the context of high blood glucose levels, contributes to the development of diabetic neuropathy (nerve damage), cataracts (eye lens clouding), and nephropathy (kidney damage).  However, it's crucial to note that Tolrestat is no longer marketed in many regions due to safety concerns.

### Dosage
Because Tolrestat is no longer commercially available, specific dosage information is not readily accessible for general use.  Prescribing information, were it available, would have detailed dosage regimens for adults and children based on factors such as the specific condition being treated, the patient's weight, and other relevant medical factors.  Different formulations (e.g., tablets, capsules, syrup) might have had varying dosage recommendations.  **It is imperative not to attempt to obtain or use Tolrestat without a prescription from a qualified healthcare professional.**

### Side Effects
While detailed frequency data may not be easily accessible due to the drug's discontinuation, Tolrestat's significant safety concerns centered around liver toxicity.  Reported side effects included:

*   Liver damage (hepatotoxicity), ranging in severity from mild elevation of liver enzymes to severe, life-threatening liver failure.
*   Other potential side effects, whose frequency is unknown without access to archived clinical trial data, could have included gastrointestinal issues (nausea, vomiting, diarrhea), allergic reactions (rash, itching, swelling), and other less common adverse events.

**It is essential to seek immediate medical attention if any adverse effects occur.**

### How it Works
Tolrestat works by inhibiting the enzyme aldose reductase.  This enzyme plays a key role in the polyol pathway, a metabolic pathway that converts glucose to sorbitol.  In individuals with diabetes, elevated blood glucose levels lead to increased sorbitol production. The accumulation of sorbitol in various tissues, such as the nerves, lens of the eye, and kidneys, is believed to contribute to the development of diabetic complications. By inhibiting aldose reductase, Tolrestat reduces sorbitol production, potentially mitigating the damage caused by its accumulation.

### Precautions
Tolrestat's use was discontinued due to serious safety concerns, primarily the risk of severe liver damage and even death.  Therefore,  **Tolrestat should not be used under any circumstances.**  The drug's profile, were it still marketed, would have included warnings for individuals with pre-existing liver conditions, those taking other medications that could affect the liver, and pregnant or breastfeeding women.  Drug interactions with other medications were also likely a concern given the hepatotoxicity.

### FAQs

* **Q: Where can I find Tolrestat?** A: Tolrestat is no longer commercially available due to safety concerns.  Attempting to obtain it through unofficial channels is strongly discouraged and potentially dangerous.

* **Q: What are the alternatives to Tolrestat for managing diabetic complications?** A:  Several other treatments are available for managing diabetic neuropathy, nephropathy, and cataracts.  Consult with your doctor or a qualified healthcare professional to discuss the most appropriate and safe options for your specific situation.

* **Q: Is Tolrestat safe?** A: No, Tolrestat was associated with a significant risk of severe liver toxicity and death, leading to its withdrawal from the market.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Consult with a healthcare professional before starting or stopping any medication, including Tolrestat (which is no longer available).  This information does not provide a complete overview of Tolrestat's profile given its removal from the market, and some details are inferred based on the general properties of aldose reductase inhibitors and the information available on the drug's past use.
